Business Context and Reporting Period
This Form 8-K Current Report was filed by Herbalife Ltd. on April 1, 2008. The filing discloses the execution of an amended and restated employment agreement with Michael O. Johnson, Chairman and Chief Executive Officer, effective March 27, 2008. The report details compensatory arrangements, including salary, bonuses, and equity awards.
Key Financial Metrics and Compensation
The filing does not provide general corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on executive compensation terms:
- Base Salary: $1,200,000 annually.
- Target Bonus: Up to 200% of base salary (maximum 300% based on performance targets).
- Sign-on Bonus: $1,500,000 cash payment.
- Restricted Stock Units (RSUs): Grant of 130,480 units.
- Stock Appreciation Rights (SARs): Grant covering 759,790 shares with a base price of $48.64.
Material Changes
The primary material change is the formalization of Mr. Johnson's employment terms and the granting of significant equity awards. The agreement establishes specific vesting schedules and performance hurdles for the equity grants, differing from prior arrangements by defining precise stock price targets for SAR vesting.
Outlook, Risks, and Unusual Items
Equity Vesting Conditions:
- RSUs: Vest 30% annually over three years (2009-2011) and 10% in 2012, contingent on continued employment.
- SARs: Vesting is performance-based. 363,670 SARs require the stock price to exceed $67.33 for 30 consecutive days; 396,120 SARs require the price to exceed $80.43 for 30 consecutive days by March 27, 2012.
- Without Cause/Good Reason: Entitles Mr. Johnson to a lump-sum cash payment equal to two times his base salary plus two times his base salary (bonus level), plus accelerated vesting of equity and medical benefits until age 65.
- Death/Disability: Entitles Mr. Johnson to pro-rata bonus, accelerated vesting, and medical benefits until age 65.
- Quiet Period Penalty: An additional $250,000 cash payment if termination occurs during a trading blackout period.
Investor Verification Checklist
- Verify the total potential cash payout in a "Without Cause" termination scenario (Base + Bonus Level + Sign-on implications).
- Confirm the current stock price relative to the $67.33 and $80.43 vesting hurdles for the SARs.
- Review the full text of Exhibit 10.1 for specific definitions of "Cause" and "Good Reason."
- Assess the impact of the 759,790 SARs and 130,480 RSUs on potential future share dilution.